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Epithelial cellsWhilst androgen ablation therapy is used to treat locally advanced or metastatic forms of prostate cancer, side-
effects can include the emergence of an androgen-independent neuroendocrine cell population which is
associated with poor prognosis. Here we have examined how cyclic AMP elevation regulates early events in the
neuroendocrine differentiation process.Wedemonstrate that selective activation of protein kinase A is necessary
and sufﬁcient for cyclic AMP (cAMP) elevation to rapidly promote a neuroendocrine phenotype in LNCaP cells
independent of de novo protein synthesis. Furthermore, the effects of cAMP could be recapitulated by inhibition
of RhoA signalling or pharmacological inhibition of Rho kinase. Conversely, expression of constitutively active
Gln63Leu-mutated RhoA acted as a dominant-negative inhibitor of cAMP-mediated NE phenotype formation.
Consistent with these observations, cAMP elevation triggered the PKA-dependent phosphorylation of RhoA on
serine 188, and a non-phosphorylatable Ser188Ala RhoAmutant functioned as a dominant-negative inhibitor of
cAMP-mediated neuroendocrine phenotype formation. These results suggest that PKA-mediated inhibition of
RhoA via its phosphorylation on serine 188 and the subsequent inhibition of ROCK activity plays a key role in
determining initial changes in cellular morphology during LNCaP cell differentiation to a neuroendocrine
phenotype. It also raises the possibility that targeted suppression of this pathway to inhibit neuroendocrine cell
expansion might be a useful adjuvant to conventional prostate cancer therapy.
© 2012 Elsevier Inc. Open access under CC BY license.1. Introduction
Prostate cancer (PCaI) is the most frequently diagnosed male-
speciﬁc malignancy and causes the greatest number of male cancer-
related deaths after lung cancer [1]. Prostate cell growth is reliant on
the presence of androgens such as testosterone with traditional
therapeutic strategies focussing on androgen ablation therapy [1].
However, such therapies have unwanted side effects including mood
alterations, sexual dysfunction, skeletal complications and increased
risk of diabetes and cardiovascular events [2,3], and selection for the
emergence of androgen-independent cells such as neuroendocrine
(NE) cells [1]. NE cells play a key role in governing differentiation and
proliferation of the developing prostate gland and, whilst their role inMP; NE, neuroendocrine; PSA,
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 license.the mature gland is less well deﬁned, it is thought that they play
important regulatory roles in secretion [4].
Clinically, PCa incidence and progression are assessed via monitoring
serum prostate speciﬁc antigen (PSA) levels. However PSA is limited as a
biomarker due to issues with false-positive results and lack of
discrimination between aggressive and non-aggressive diseases [5].
Thus other markers are being assessed for use in the diagnosis and
prognosis of PCa. Recently, the presence of NE cell products as a
prognosticmarker in PCa has come under investigation [6]. The presence
of NE cells has been described in 47 to 100% of prostatic adenocarci-
nomas [7]. Expansion of the NE cell population has been described in
late-stage PCa and has been suggested to be indicative of poor patient
prognosis [6]. NE cells form foci of non-dividing cells surrounded by
regions of proliferating tumour cells due to the release of mitogenic
compounds such as bombesin [8] and chromogranin A [9]. Due to their
resistance to many conventional chemotherapeutics, it is possible that
inhibition of NE cell differentiation may be a useful avenue by which to
complement existing therapies and thus prevent expansion of this cell
type in late-stage PCa.
The LNCaP cell line was isolated from a lymph node metastasis of
PCa [10] and is a well-established model of NE differentiation in PCa.
LNCaP cells undergo differentiation to a NE phenotype under a
number of conditions including androgen deprivation [11], chronic
exposure to IL-6 [12], constitutive activation of gp130 [13] and
elevation of intracellular cyclic AMP (cAMP) levels [7,12,14]. Initially,
1505S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514the differentiation of these cells to a NE phenotype is reversible [15]
but chronic exposure to cAMP-elevating agents ultimately results in
the terminal differentiation of LNCaP cells [7]. Inhibition of the initial
stages of NE differentiation in prostate epithelial cells may therefore
be a useful adjuvant to conventional chemotherapeutic strategies. Of
particular interest is the role of cAMP-mediated signalling in this
phenomenon and elucidation of the signalling mechanisms involved
in initial NE differentiation.
Classically, cAMP was thought to exert its intracellular effects
exclusively via activation of cAMP-dependent protein kinase (PKA).
Binding of cAMP to the PKA holoenzyme promotes dissociation of the
regulatory and catalytic subunits [16,17] and allows the catalytic
subunits of PKA to phosphorylate downstream targets, such as the
cAMP responsive element binding protein (CREB) [18–20]. Phosphor-
ylation of transcription factors such as CREB is onemechanismbywhich
elevation of intracellular cAMP concentrations can alter gene transcrip-
tion. However it is now appreciated that in addition to PKA, cAMP can
activate the exchange proteins directly activated by cAMP (EPACs) to
promote intracellular effects [21–23]. It has been previously demon-
strated that over-expression of constitutively active PKA catalytic
subunits in LNCaP cells can promote NE differentiation in the absence
of other stimuli [14], suggesting that PKA activation is sufﬁcient to
recapitulate this phenomenon following cAMP elevation. Furthermore,
PKA-differentiated LNCaP cells can promote the anchorage-dependent0 1 2 3 4 5 6 7 8
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Fig. 1. The ability of Fsk to induce rapid changes in LNCaP cell morphology is independent of de
the presence of either vehicle (0.1% (v/v) EtOH) (open circles) or 100 μM Fsk (closed circles). M
for n=3 experiments. ***pb0.001 vs. 0 h, ###pb0.001 vs. vehicle at same time point. Panel B:
or 100 μMprotein synthesis inhibitor emetine prior to stimulationwith vehicle (0.1% (v/v) EtOH
the experiment (0 h) and following the 1 h stimulation with Fsk (post-stimulation). Panel C:
Results are presented as mean values±SEM for n=3 experiments. ***pb0.001 vs. 0 h, ###pband -independent growth of prostate cells [24], indicating that the
kinase may play a crucial role in PCa progression. The ability of cAMP
elevation to promote a neuronal cell phenotype is not restricted to
LNCaP cells. In the PC12 pheochromocytoma cell line, elevation of cAMP
can promote neurite outgrowth [25], Unlike LNCaP cells in which
differentiation can be induced through constitutive PKA activity, PC12
cells require signalling through EPAC for neuronal differentiation [26].
Clearly different mechanisms are used in the two cell types to promote
activation of similar downstream effectors. Of particular interest are the
roles of the RhoGTPaseswhich control cell morphology andmotility via
regulation of the actin cytoskeleton. Of particular interest is the role of
RhoA, as this GTPase has been described as a master regulator of
dendrite morphogenesis [27]. Neurite outgrowth from PC12 cells in
response to basic ﬁbroblast growth factor (bFGF) and nerve growth
factor (NGF) arises due to p190RhoGAP andARAP3-mediated inhibition
of RhoA [28,29]. Furthermore, activation of RhoA has been shown to
inhibit NGF-induced neuronal extension and to promote neurite
retraction in PC12 cells. In this study, NGF was shown to inhibit RhoA
activity via PKA-mediated phosphorylation on Ser188, a processwhich is
required for NGF-induced neurite extension in PC12 cells [30].
Here, we demonstrate that selective activation of PKA entirely
mimics the effect of cAMP elevation during initial changes in LNCaP
morphology via a process independent of de novo protein synthesis.
Furthermore, the effects of cAMP elevation on LNCaP cell morphology0 h Post-stimulation
Vehicle
Emetine
Fsk
Fsk + Emetine
novo protein synthesis. Panel A: LNCaP cells were pre-incubated for the indicated times in
ean dendrite outgrowthwas determined and results are presented as mean values±SEM
LNCaP cells were pre-incubated for 2 h in the presence of either vehicle (0.1% (v/v) DMSO)
) or 10 μMFsk for a further 1 h. Phase contrast imageswere captured immediately prior to
Mean dendrite outgrowth was assessed at 1 h post-stimulation as described previously.
0.001 vs. vehicle at same time point.
1506 S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514can be almost entirely recapitulated following inhibition of RhoA
signalling and that RhoA itself is a PKA substrate in these cells. These
results suggest that PKA-mediated inhibition of RhoA plays a key role
in determining cellular morphology during initial LNCaP cell differ-
entiation to a NE phenotype.2. Materials and methods
2.1. Materials
LNCaP cells were purchased from the American Type Culture
Collection (ATCC). pRK plasmids containing wild-type and constitu-
tively active myc epitope-tagged RhoA were kind gifts from Professor
Alan Hall (Memorial Sloan-Kettering Cancer Centre, New York) whilst
Ser188Ala-mutated myc-tagged RhoA was generously donated by
Professor Keith Burridge (University of North Carolina School of
Medicine, North Carolina). Rhodamine-conjugated phalloidin and the
Lipofectamine 2000 transfection reagent were purchased from
Invitrogen, Paisley, UK. Myristoylated PKA inhibitor 14-22 amide
(myrPKI14-22), H89, Y27632, N6-benzoyl-cAMP (6-Bnz-cAMP), rabbit
polyclonal antibody to pSer188RhoA and forskolin (Fsk) were procuredVehicle
10 nM myr.PKI
10 µM Fsk
10 µM Fsk +  
10 nM myr.PKI
0 h Post-stimulation
A
Fig. 2. The ability of Fsk to induce changes in LNCaP cell morphology is PKA dependent. Pa
DMSO) or 10 nM PKA inhibitor myr.PKI14-22 prior to stimulation with vehicle (0.1% (v/v)
experiment (0 h) and following the 1 h stimulation with Fsk (post-stimulation). Panel B: Me
the longest dendrite for 30 cells in ﬁve random ﬁelds for each treatment at each time point. R
vs. 0 h, ###pb0.001 vs. vehicle at same time point, +++pb0.001 vs. Fsk at 1 h. Panel C:
presence and absence of myr.PKI14–22 as described above but stimulated for 15 min in the pr
lysates were equalised for protein content and volume prior to fractionation via SDS-PAGE
activity. Equal protein loading was assessed by determining total ERK1,2 levels.from Merck Chemicals Ltd., Nottingham, UK. Cell-permeable C3 trans-
ferase (C3T) was purchased from Universal Biologicals Ltd., Cambridge,
UK. Complete protease inhibitor cocktail tablets were purchased from
Roche Applied Science, Welwyn, UK. Antibodies to RhoA, ERK1/2 and
phosphorylated PKA substrate were purchased from Cell Signalling
Technology, Hitchin, UK. Antibodies to phospho-Ser133 (pSer133) CREB
were purchased from Abcam, Cambridge, UK. Antibody to receptor of
activated C kinase 1 (RACK1) (IgM clone) was purchased from BD
Transduction Laboratories, Oxford, UK. Enhanced chemiluminescence
reagent and 3H-leucine (speciﬁc activity 1.48–2.22 TBq/mmol) were
purchased from Perkin-Elmer Life Sciences, Waltham, MA. All other
reagents were purchased from Sigma-Aldrich, Poole, UK.2.2. Cell culture
LNCaP cells were cultured in a humidiﬁed atmosphere at 37 °C, 5%
(v/v) CO2. Cells were cultured in RPMI1640 medium supplemented
with 10%(v/v) foetal bovine serum, 100 U/ml penicillin, 100 μM
streptomycin, 1 mM L-glutamine and 1 mM sodium pyruvate. In
order to aid cell adherence, all plasticware was coated with 0.1 mg/ml
poly-D-lysine HBr prior to use.14-22
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nel A: LNCaP cells were incubated for 1 h in the presence of either vehicle (0.1% (v/v)
EtOH) or 10 μM Fsk. Phase contrast images were captured immediately prior to the
an dendrite length was determined as the distance between the cell body and the tip of
esults are presented as mean values±SEM for n=3 separate experiments. ***pb0.001
Inhibitor efﬁcacy was assessed by including control cells which were incubated in the
esence of vehicle or 10 μM Fsk to induce phosphorylation of CREB on Ser133. Whole cell
and subsequent immunoblotting for pSer133CREB as a downstream indicator of PKA
1507S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–15142.3. Cell transfection
LNCaP cells were seeded into 6 cm tissue culture dishes and allowed
to grow to 40–50% conﬂuence. On the day of transfection, growth
medium was replaced with RPMI 1640 medium supplemented as
described above but lacking antibiotics. Plasmid preparations were
defrosted on ice and transfections performed using Lipofectamine 2000
(Invitrogen) as per manufacturer's instructions. The optimal ratio of
DNA to Lipofectamine 2000 was found to be 1 μg DNA to 4 μl
Lipofectamine 2000. Transfected cells were incubated overnight and
cell medium replaced with fresh antibiotic-free growth medium. Cells
were then incubated for a further 24 h prior to use in experiments.
2.4. Cell stimulation
LNCaP cells were seeded into 6-well tissue culture dishes and
grown to 70% conﬂuence prior to experiments. Where appropriate,
cells were pre-incubated with the appropriate inhibitor as speciﬁed in
individual experiments prior to stimulation with 10 μM Fsk. Cell
stimulation was quenched by washing cells three times in ice-cold
PBS prior to lysis in radioimmunoprecipitation assay buffer contain-
ing 50 mM HEPES (pH 7.5), 150 mM sodium chloride, 1%(v/v) Triton
X-100, 0.5%(w/v) sodium deoxycholate, 0.1%(w/v) SDS, 5 mM EDTA
(pH 8), 10 mM sodium ﬂuoride, 10 mM sodium phosphate, 2 μg/mlVehicle
100 µM 6-Bn
10 µM Fsk
10 µM Fsk + 
100 µM 6-Bn
0 h Post-stimulation 
A
Fig. 3. Selective activation of PKA recapitulates the effects of Fsk on LNCaP cell morpholo
stimulation with vehicle (0.1% (v/v) EtOH, 1% (v/v) DMSO), 10 μM Fsk and/or 100 μM PKA-
assessed as described above. Results are presented as mean values±SEM for n=3 separate ex
vs. Fsk at 1 h. Panel C: The efﬁcacy of 6-Bnz-cAMP and Fskwas demonstrated in cells stimulated
and fractionated via SDS-PAGE and activation of PKAdetermined by immunoblottingwith an an
band that conveniently serves as a control for equal protein loading.benzamidine, 2 μg/ml soybean trypsin inhibitor, 100 μM PMSF and
complete protease inhibitor cocktail. Following the addition of 75–
100 μl RIPA buffer, samples were solubilised for 30 min on ice. Samples
were stored at –80 °C until determination of protein concentration and
subsequent immunoblotting. Determination of protein concentration
and immunoblotting was performed as described previously [31].
2.5. Microscopy and measurement of dendrite outgrowth
Phase contrast microscopy was performed using a Zeiss Axiovert
40 CFL microscope with an AxioCam MRc5 camera attachment. Five
random ﬁelds per treatment were captured and analysed using Image
J software. Dendrite outgrowth was determined by measuring the
greatest distance between the cell body and the tip of the extended
dendrite. Thirty cells per ﬁeld were analysed at random and each
experiment was repeated three times.
2.6. Membrane translocation of RhoA
Cellular membranes from LNCaP cells were isolated as described
by Thibault et al. [32]. Brieﬂy, LNCaP cells were seeded into 10 cm
tissue-culture dishes and grown to 60–70% conﬂuence. Upon the day
of experiment, culture medium was replaced with 5 ml/dish of fresh,
supplemented RPMI1640 medium and stimulated as described forz-cAMP 
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gy. Panel A: Phase contrast images of LNCaP cells were captured at 0 h and 1 h post-
selective cAMP analogue 6-Bnz-cAMP. Panel B: Changes in mean dendrite length were
periments. ***pb0.001 vs. 0 h, ###pb0.001 vs. vehicle at same time point, +++pb0.001
for 15 min.Whole cell lysates were subsequently prepared, equalised for protein content
ti-phospho-PKA substrate antibody. * indicates a non-speciﬁcally labelled immunoreactive
0 
h
 
6 
h
po
st
-s
tim
u
la
tio
n
0 
h
 
6 
h
po
st
-s
tim
u
la
tio
n
0 
h
 
6 
h
po
st
-s
tim
u
la
tio
n
0 
h
 
6 
h
po
st
-s
tim
u
la
tio
n
0
10
20
30
40
C D
***
###
***
### ***###
***
###
***
###
Vehicle Fsk C3T C3T+Fsk
A B
6 h
0 h
Post-stimulation
Vehicle 10 µM Fsk
0 h
6 h
Post-stimulation 
4 µg/ml C3T 4 µg/ml C3T
+ 10 µM Fsk
Fig. 4. Blockade of Rho activation mimics the effects of PKA. LNCaP cells were plated into 6-well plates and incubated for 6 h with either vehicle (2% (v/v) PBS) (Panel A) or 4 μg/ml
C3T (Panel B) prior to stimulation with either vehicle (0.1% (v/v) EtOH) or 10 μM Fsk for 1 h. Images were captured as described at 0 h (0 h), 6 h post-stimulation (6 h) and
following stimulation with Fsk (post-stimulation). Panel C: Changes in LNCaP morphology consistent with NE-like differentiation were assessed via increases in mean dendrite
length. Results are represented as mean values±SEM for n=3 separate experiments. ***pb0.001 vs. 0 h, ###pb0.001 vs. vehicle. Panel D: Protein sequences corresponding to the
known human Rho family members retrieved from the UniProt knowledge base were aligned using ClustalW (http://www.clustal.org/). The N-terminus of RhoA was then
compared to other family members in order to assess whether they showed similar motifs to those implicated in the binding of C3T to RhoA and subsequent ADP ribosylation (47).
X = site of ADP-ribosylation, equivalent to N41 X = residues involved in C3T recognition, equivalent to R5, K6, E47 and E54 X = residues involved in correct ternary complex
formation between Rho, C3T and NAD+, corresponding to E40 and V43. All amino acid positions refer to the position of these residues in RhoA.
1508 S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514individual experiments. Following stimulation, cells were washed 3
times in 5 ml/dish ice-cold PBS and harvested into 300 μl of ice-cold
PBS. Cells were pelleted via centrifugation at 5000 g for 5 min at 4 °C
and subsequently resuspended in 500 μl of ice-cold KCl relaxation
buffer containing 100 mM KCl, 50 mM HEPES pH 7.2, 5 mM NaCl,
1 mMMgCl2, 0.5 mMEGTA, 100 μMPMSF, 2 μg/ml benzamidine, 2 μg/ml
soybean trypsin inhibitor and a complete protease inhibitor. Lysates
were sonicated for 2×20 s on ice prior to the removal of unbroken cells
and nuclei via centrifugation at 700 g for 7 min at 4 °C. The resultantsupernatant was transferred to a 13×51 mm Ultra-Clear™ centrifuge
tube and volumes were adjusted to 5 ml in KCl relaxation buffer. Cell
membranes were harvested by subsequent ultracentrifugation at
50,000 g for 45 min at 4 °C. The supernatant was discarded and the
resultant pellet washed in 5 ml of KCl relaxation buffer as described. The
washed cell pellet was resuspended in 100 μl of RhoA translocation
buffer containing 0.25 M Na2HPO4, 0.3 M NaCl, 2.5% (w/v) SDS, 100 μM
PMSF, 2 μg/ml benzamidine, 2 μg/ml soybean trypsin inhibitor and a
complete protease inhibitor. To ensure sufﬁcient solubilisation of the
1509S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514cellular membranes, the lysates were incubated on a rotating wheel at
room temperature prior to determination of protein content and
fractionation by SDS-PAGE.
2.7. Statistical analysis
All statistical analyses were performed using Prism 4 software
(GraphPad, San Diego, CA). Data were tested for normality using the
Kolomogorov–Smirnov test prior to analysis via either one-way
ANOVA with Bonferroni's correction or Kruskal–Wallis test with
Dunn's correction.
3. Results
It has been demonstrated previously that over-expression of
constitutively active catalytic PKA subunits can induce terminal NE-like
differentiation in LNCaP cells [14] and that PKA-differentiated LNCaP
cells can promote the anchorage-independent growth of neighbouringVector myc.RhoA.WT
A
Fig. 5. Expression of constitutively active RhoA inhibits Fsk-induced changes in LNCaP cell m
plates at a density of 3×105 cells per well and transfected with 1 μg of either pRK5, myc
stimulated with vehicle (0.1% (v/v) EtOH) and 10 μM Fsk and images captured as described a
with NE-like differentiation were assessed via increases in mean dendrite length. Results are
###pb0.001 vs. vehicle, +++pb0.001 vs. pRK5. Panel C: Expression of RhoA mutants wa
labelled immunoreactive band that serves as a control for equal protein loading.cells [24]. However, the role of PKA in the initial response to elevated
cAMP levels in LNCaP cells has not been addressed. Time course
experiments in LNCaP cells treated with 10 μM Fsk, a diterpene
activator of membrane adenylyl cyclases [33], revealed a time-
dependent change in cell morphology consistent with NE-like differ-
entiation and which was detectable at 1 h post-stimulation and
sustained for at least 24 h (Fig. 1A). As described by others, the change
in LNCaP morphology was characterised by dendrite-like cellular
protrusions and branching and rounding of the cell body (Fig. 1B)
[12,14,24]. These morphological changes were not observed in either
the normal prostate epithelial PZ-HPV-7 cell line or in the tumour-
derived DU145 prostate epithelial cell line (data not shown), suggesting
that they are speciﬁc to the LNCaP cell line.Whilst the cellular processes
observed in LNCaP cells morphologically resemble dendrites, they
cannot be formally classed as such due to the early time point post-
stimulation theywere observed. However, for the purpose of this study,
these cellular processeswill be referred to as dendrites. Importantly, the
ability of Fsk to induce changes in LNCaP cell morphology did notmyc.RhoA.Q63L
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Fig. 5 (continued).
1510 S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514require de novo protein synthesis, as pre-treatment with protein
synthesis inhibitor emetine at a maximally effective concentration (as
determined by inhibition of 3H-leucine incorporation into cellular
protein) did not signiﬁcantly alter the observed changes in cell
morphology (Fig. 1B,C).
In order to assess the role of PKA in this phenomenon, LNCaP cells
were pre-incubated with the highly PKA-selective cell-permeable
peptide inhibitor myr.PKI14–22 [16] prior to stimulation with Fsk.
Treatment with Fsk induced an increase in mean dendrite length from
22.41±0.78 μm to 33.28±0.99 μm post-stimulation (***pb0.001 vs.
0 h, ###pb0.001 vs. vehicle; Fig. 2A,B) which was signiﬁcantly
inhibited by pre-incubation with myr.PKI14–22 (mean dendrite length
post-stimulation=26.44±0.86 μm, Fig. 1, pb0.001 vs. Fsk-stimulation
alone; Fig. 2A, B) at a concentration atwhich it was effective in blocking
PKA-mediated Ser 133 phosphorylation of CREB (Fig. 2C). Incubation
with either myr.PKI14-22 alone or vehicle failed to induce any change in
cellular morphology (Fig. 2A, B).
Whilst the above results indicate that PKA activation is necessary for
the NE-like differentiation of LNCaP cells, it does not indicate whether
this process is sufﬁcient to induce changes in cell morphology at
physiological levels of PKA expression. To address this issue, LNCaP cells
were treated with the PKA-selective activator 6-Bnz-cAMP [34] in the
presence and absence of Fsk. Treatment with 100 μM 6-Bnz-cAMP
entirely recapitulated the effects of Fsk treatment on LNCaP cell
morphology with mean dendrite length increasing from 18.68±0.49
to 31.03±0.65 μm (pb0.001 vs. 0 h and vehicle) and from 18.14±
0.45 μm to 35.11±0.71 μm (pb0.001 vs. 0 h and vehicle) following
stimulation with 6-Bnz-cAMP and Fsk respectively (Fig. 3A, B). The
efﬁcacy of 6-Bnz-cAMP and Fsk in activating PKA was conﬁrmed using
anti-phospho-PKA substrate antibody, which demonstrated that both
stimuli increased PKA-mediatedphosphorylation in extracts from treated
cells (Fig. 3C) The lack of additivity between 6-Bnz-cAMP and Fsk in
mediatingNE-like differentiation, coupledwith the lack of any signiﬁcant
effect of EPAC activator 007 at concentrations capable of inducing EPAC-
regulated gene SOCS-3 [31] (data not shown), indicate that PKA is thedominant effector in this process, in contrast to the synergistic
interactions observed between PKA and EPACs in other systems [34].
Activated PKA exerts its effects via Ser/Thr phosphorylation of
downstream targets, thereby altering their activity and/or subcellular
localisation [20,35–37]. Interestingly, one reported downstream
substrate of PKA is RhoA, a member of the Rho family of small
GTPases [38]. PKA-mediated phosphorylation of Ser188 inactivates
RhoA by preventing dissociation of inactive GDP-bound RhoA from
Rho-GDP-dissociation inhibitor (Rho–GDI), thus trapping RhoA in an
inactive state [39]. RhoA plays an important role in cellular adherence
andmorphology by promoting the formation of stress ﬁbres arising from
the bundling of actin microﬁlaments which form the cell cytoskeleton
[40,41]. Disruption of the actin polymerisation with cytochalasin B
mimicked the effects of Fsk on changes in cell morphology with no
evidence of additive interactions (data not shown), suggesting that Fsk is
acting to disrupt actin organisation in LNCaP cells. To determinewhether
these changes in cell morphology were due to inhibition of Rho GTPase-
mediated signalling, LNCaP cells were pre-treated with a cell-permeable
Clostridium botulinum C3 transferase (C3T) for 6 h prior to stimulation
with Fsk. C3T inhibits RhoA activation via ADP-ribosylation of Asn41 and
is selective for RhoA, RhoB and RhoC members of the Rho family [42].
Treatment of cells with C3T in the absence of Fsk was sufﬁcient to
produce a signiﬁcant increase in mean dendrite length from 24.00±
0.79 μm to 33.76±1.07 μm (Fig. 4A–C, pb0.001 vs. vehicle and 0 h). The
increase in mean dendrite length observed with C3T alone was
comparable to that seen in cells treated with Fsk alone with mean
dendrite length increasing from 27.38±0.79 μm at 0 h to 32.85±
0.92 μm post-stimulation (pb0.001 vs. 0 h and vehicle). Combined
incubation of LNCaP cells with C3T for 6 h followed by treatment with
Fsk for 1 h failed to induce a greater increase in mean dendrite length
than that observed with Fsk or C3T alone (Fig. 4A–C, mean dendrite
length=24.29±0.84 μm and 36.42±1.16 μm at 0 h and post-
stimulation respectively (pb0.001 vs. 0 h and vehicle)). The lack of any
additivity between C3T and Fsk treatments suggests that the two are
converging on a common mechanism responsible for the observed
changes in LNCaP cell morphology. Of the known Rho family members,
only RhoA, RhoB and RhoC possess the correct conﬁguration of amino
acids to bind and become ADP-ribosylated by C3T (Fig. 4D), thus the
effects observed are unlikely to arise from effects on other Rho family
members such as RhoG which has also been implicated in neuronal
differentiation [43]. However, these observations in isolation do not
demonstrate that RhoA itself is essential in this process.
To address this, LNCaP cells were transfected with either vector or
a myc-tagged wild-type RhoA (myc.RhoA.WT) or constitutively active
GTPase-deﬁcient mutant (myc.RhoA.Q63L) prior to treatment with
Fsk. Immediately prior to transfection, all cells appeared identical,
whilst at 48 h post-transfection it was noticed that cells expressing
myc.RhoA.Q63L displayed shorter cell processes (Fig. 5A, B). Further-
more, expression of constitutively active RhoA signiﬁcantly blocked the
ability of Fsk to induce dendrite-like outgrowth (Fig. 5A, B, pb0.001 vs.
Fsk), suggesting that RhoA activation inhibits Fsk-mediated changes in
LNCaP cell morphology. This was not simply an effect of RhoA over-
expression as cells transfected with myc.RhoA.WT demonstrated
changes in cell morphology consistent with that seen in vector-
transfected cells (Fig. 5A, B). Moreover immunoblotting with anti-myc
tag antibody demonstrated that both WT and Q63L RhoA were
expressed at similar levels (Fig. 5C). These results demonstrate that
activated RhoA can inhibit the ability of Fsk to induce changes in LNCaP
cellular morphology associated with NE differentiation, suggesting that
RhoA is the primary Rho GTPase involved in this phenomenon.
In neuronal cells, it has been suggested that PKA-mediated inhibition
of RhoA activation can promote changes in cellular morphology via a
decreased association with the downstream effector Rho-associated
protein kinase (ROCK) II [44]. However, unlike previous cell models
which derive from the neural crest, LNCaP cells are thought to originate
from epithelial stem cells due to their expression of epithelial markers
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of such a cell type has not been previously investigated. To further
demonstrate that RhoA activation is important in initial Fsk-induced
changes in LNCaP cell morphology, cells were incubated with the ROCK-
selective inhibitor Y27632 [45] prior to stimulationwith Fsk. As expected,
treatment with Y27632 alone promoted an increase in mean dendrite
length (Fig. 6A, B, pb0.001 vs. vehicle and Fsk) which was less than that
seen with Fsk treatment alone. However, the lack of additivity between
Fsk and Y27632 (Fig. 6A, B) suggests that the two pathways exert their
effects via a common pathway. These results serve to conﬁrm that
inhibition of RhoA-mediated signalling plays a pivotal role in PKA-
induced changes in LNCaP cell morphology and that the Rho/ROCK
signalling pathway is involved downstream of RhoA.
It has beendemonstrated that PKA canphosphorylate RhoA at Ser188
in vitro and in vivo [38], resulting in the inactivation of downstream
RhoA signalling [39,46–48]. To determine whether cAMP elevation
promoted serine phosphorylation of RhoA in LNCaP cells and whether
this was an important mechanism in mediating the changes in cell
morphology observed, LNCaP cells were transfected with vector, myc-
taggedwild-type RhoA and amyc-tagged S188Amutant of RhoA prior to
stimulation with vehicle or Fsk for 1 h. Whilst all cells displayed similar
morphology prior to stimulation, expression of myc.RhoASer188Ala in
these cells signiﬁcantly inhibited Fsk-stimulated increases in mean
dendrite length, indicating that phosphorylation of Ser188 of RhoA is
necessary for the Fsk-induced changes in LNCaP cell morphologyFig. 6. Pharmacological inhibition of ROCK mimics the effects of PKA. Panel A: LNCaP cells
inhibitor Y27632 for 1 h prior to stimulation with either vehicle (0.1% (v/v) EtOH) or 10 μM
following stimulation. Panel B: Mean dendrite length determined (panel B). Results are
###pb0.001 vs. vehicle at same time point, +++pb0.001 vs. Fsk at 1 h.(Fig. 7A, B). Immunoblotting of cell extracts from transfected LNCaP
cells revealed that Fsk treatment was able to stimulate phosphorylation
of Ser188 in WT RhoA but not the Ser188Ala mutant despite both being
expressed at similar levels (Fig. 7C). Consistent with observations that
Ser188 phosphorylation inhibits RhoA activity and reduces levels of
RhoA at the membrane [49], we found that Fsk treatment resulted in a
signiﬁcant decrease in levels of membrane-associated RhoA (Fig. 7D).
Sincemembrane association of RhoA is associatedwith its activation, our
data suggest that cAMP elevation can promote rapid changes in cell
morphology via PKA-mediated phosphorylation and subsequent inacti-
vation of RhoA.
4. Discussion
Upon differentiation to a NE phenotype, LNCaP cells display rounding
of the cell body and extension of dendrite-like cellular processes. We
found that, upon stimulation with the cAMP-elevating compound Fsk,
LNCaP cells underwent rapid changes in cellular morphology which
could be maximally observed within 1 h of stimulation and occurred
independently of de novo protein synthesis. Furthermore, pre-treatment
of cells with the PKA-selective inhibitor myr.PKI14–22 [16] inhibited
Fsk-induced changes in cellular morphology. Similarly, selective
activation of PKA with 6-Bnz-cAMP entirely recapitulated the effects
of Fsk and the lack of synergistic or additive interactions between Fsk
and 6-Bnz-cAMP observed suggests, in accordance with previous datawere incubated with either vehicle (0.5% (v/v) DMSO) or 5 μM of the ROCK-selective
Fsk for 1 h. Phase contrast images of LNCaP cells were captured at 0 h and immediately
presented as mean values±SEM for n=3 separate experiments. ***pb0.001 vs. 0 h,
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major cAMP sensor involved in the early morphological changes
observed in LNCaP cells. Such results are in keeping with observations
that over-expression of a constitutively active mutant of the catalytic
subunits of PKA in LNCaP cells promotes NE differentiation in the
absence of other stimuli and furthermore enhances both the anchorage-
dependent and -independent growth of PCa cells in vitro and in vivo
[14,24]. However, over-expressionmodels are not ideal as high levels of
protein expression may not be physiologically relevant and the focus of
those studies was terminally differentiated cells. To our knowledge, this
is the ﬁrst demonstration of a central role of PKA in the early
morphological changes in LNCaP cell differentiation towards a NE-like
phenotype. It should be noted here that our assessment of differentiation
is based solely on morphological changes. Gene and protein markers of
LNCaP differentiation that have been employed include neuron-speciﬁc
enolase and chromogranin A [12,15]. However undifferentiated cellsVector myc.RhoA.WT
A
Fig. 7. Expression of Ser188Ala-mutated RhoA blocks Fsk-induced changes in LNCaP cell mo
plates at a density of 3×105 cells per well and transfected with 0.5 μg of either pRK5, myc.W
(0.1% (v/v) EtOH) and 10 μM Fsk and images captured as described at 0 h (0 h) and 1
differentiation were assessed via increases in mean dendrite length. Results are represented
vs. vehicle, +++pb0.001 vs. vector. Panel C: Expression and changes in RhoA phosphory
after treatment with or without 10 μM Fsk for 1 h. Both endogenous and myc-tagged recom
Panel D: Membrane localisation of endogenous RhoA after treatment with or without 10 μ
antibody. Equalisation for membrane protein loading was assessed using anti-RACK1 antibexpress detectable levels of both proteins, and the small fold-changes in
expression that we (data not shown) and others have observed even
over sustained differentiation time courses limit their utility as
differentiation markers, particularly in examining early changes that
occur independently from new protein synthesis.
Whilst PKA can phosphorylate transcription factors such as CREB
[18–20], it is unlikely that the rapid effects seen are due to de novo gene
transcription as the rapid change in cell morphology observed was
coupled with an inability of pre-treatment with emetine to block Fsk-
mediated changes in LNCaP cell morphology under conditions in which
it completely inhibited new protein synthesis. This would suggest that
the primary mechanism governing changes in cell morphology is PKA-
mediated phosphorylation of downstream effectors. One potential
candidate was the small GTPase RhoA which plays an important role in
regulating actin cytoskeletal dynamics. It has been demonstrated
previously that PKA can directly phosphorylate RhoA in vitro onmyc.RhoA.S188A
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1513S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514Ser188 [38], which forms part of a consensus motif for PKA-mediated
phosphorylation (K185KKSG) [49]. Furthermore, substitution of this
residue to a non-phosphorylatable Ala residue inhibited cAMP-
mediated changes in NE morphology [30,44]. Moreover, inhibition of
ROCK, a downstream effector of RhoA, can also promote changes in
cellular morphology consistent with NE-like differentiation in LNCaP
cells [44]. In our study, it was found that treatment of LNCaP cells with
either C3T to inhibit RhoA or blockade of ROCK signalling using Y27632
promoted changes in cellularmorphology comparable to that seenwith
Fsk treatment alone. In accordance with these observations, over-
expression of a constitutively activemutant of RhoA inhibited dendrite-
like extensions in both the presence and absence of Fsk. Attempts to
over-express a dominant negative mutant of RhoA were unsuccessful,
due to decreased cellular adherence to the substratum which was
particularly problematic in LNCaP cells which have previously been
reported to display poor adherence even under normal culture
conditions [10]. However, taken together, these data would suggest
that PKA-mediated inhibition of RhoA signalling plays an important role
in cAMP-mediated changes in LNCaP cellularmorphology. Furthermore,
treatment with Fsk promoted an increase in pSer188RhoA which was
blocked upon prior incubation with myr.PKI14–22 and expression of
myc.RhoAS188A inhibited Fsk-induced changes in cellular morphology
in a dominant-negative fashion
Taken together these results provide compelling evidence that rapid,
early changes in LNCaP cell morphology consistent with NE-like
differentiation are governed by PKA-mediated phosphorylation of RhoA
on Ser188 and subsequent inhibition of downstream signalling. Phos-
phorylation of RhoA on this residue inhibits its actions via several
mechanisms. Firstly, pSer188RhoA remains associated with Rho-GDI
which locks RhoA in a GDP-bound, inactive state and thus prevents it
from cycling back to the activeGTP-bound form [49]. Secondly, one of the
hallmarks of RhoA activation is its translocation to the cell membrane,however association with Rho-GDI sequesters Ser188-phosphorylated
RhoA in the cytoplasm [39,48], thus preventing it from exerting any
effects at the membrane. Stimulation with Fsk decreased membrane
association of RhoA in LNCaP cells, further suggesting inactivation of
RhoA. Thirdly, it has been observed that pSer188RhoA displays a
decreased capacity to bind and activate its downstream effector ROCK
[30]. Whilst RhoA has many downstream effectors, the observation that
Y27632 can recapitulate the effects of cAMP elevation suggests that
RhoA/ROCK signalling plays the primary role in this phenomenon.
However, whilst likely to play a central role in early differentiation in
LNCaP cells, the PKA/RhoA/ROCK pathway suggested here is by nomeans
exclusive. This is particularly pertinentwhen considering the observation
that overexpression of myc.Ser188AlaRhoA failed to completely block
Fsk-induced changes in cell morphology, implying that other signalling
pathways are potentially involved in mediating PKA's effects.
Whilst PC12 cells differ from LNCaP cells in that integration of both
PKA and EPAC-regulated signals are required for neurite outgrowth, a
role for PKA-mediated inhibition of RhoA downstream of the NGF
receptor has been described. In this study, phosphorylation of RhoA on
Ser188 was reported [30] although other pathways have been
implicated in NGF-mediated inhibition of RhoA. It has been suggested
that both basic ﬁbroblast growth factor- and NGF-mediated neurite
outgrowth in these cells is facilitated by p190RhoGAP and ARAP3-
mediated inhibition of RhoA [28,29]. It is possible that the relative
importance of the different signalling pathways may be temporally
regulated. Both studies investigated the role of RhoA in neurite
outgrowth in PC12 cells. However, whilst the recent work by Jeon and
co-workers investigated signalling pathways activated following NGF
and bFGF at several hours post-stimulation [28,29], the work by Nusser
and co-workers [30] investigated the impact of NGF on RhoA at 20 and
120 min post-stimulation. It is therefore possible that the immediate
changes in cell morphology which we have investigated arise primarily
1514 S.E. Jones, T.M. Palmer / Cellular Signalling 24 (2012) 1504–1514through PKA-mediated phosphorylation of RhoA on Ser188 but that
p190RhoGAP and ARAP3 may play a role in maintaining these changes
at later time points. Our data suggest that PKA-mediated phosphory-
lation of RhoA on Ser188 and subsequent inhibition of ROCK signalling
is the dominant signalling pathway involved in rapid changes in LNCaP
cellular morphology.
Whilst much work has focused on terminal differentiation of LNCaP
cells to a NE phenotype, there is little published data on pathways
involved in the early stages of this process during which therapeutic
intervention may be most beneﬁcial. It is possible therefore that
selective inhibition of the RhoA/ROCK signalling pathway by manipu-
lation of cAMP-mediated signalling may prove an effective and novel
adjuvant to current therapeutic strategies.
5. Conclusions
• Elevation of cAMP rapidly initiates the development of a
neuroendocrine-like phenotype in LNCaP prostate epithelial cells.
• PKA activation is necessary and sufﬁcient for initiation of the
phenotype.
• PKA stimulates phosphorylation of RhoA on Ser188, and expression
of Ser188Ala-mutated RhoA blocks PKA-mediated development of
the neuroendocrine-like phenotype.
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